David Beadle
CEO of APOBEC Discovery Ltd.David has over 30 years experience in the life sciences industry from early stage drug development through to product commercialisation, a large proportion of which has been in the field of oncology. As well as having served as a board member and advisor to several therapeutics companies, David was also MD of Global Healthcare Strategy for the equities division at UBS investment bank. He is a director of the MORCure rare disease charity.
Patrick Beldon
CEO of Cortirio
Bridgeen Callan
CEO of klas therapeutics
Giorgio Castagneto Gissey
CEO of Keyron LTD
Tim Craft
Founder/CEO of Somnus Scientific
Brendan Darby
CEO of Marama Labs
Mike De Leeuw
CEO of OncoLize BV
Julian Dye
Founder & CEO of Oxartis Ltd
Mohammad El Hajj
Co-founder & CEO of Bright Biotech
Colin Freund
CEO of Athernal Bio
Rebecca Goss
CEO of X-Genix
Oliver Hancox
CEO of Astratus Limited
Nataly Hastings
CEO of Cellestial Health Ltd
Julian Howell
CEO of PharmaKrysto
James Jackson
CEO of Digostics
Michael Jones
CEO of Cell Guidance Systems
Gray Kueberuwa
CEO of ImmunokeyImmunoKey is a pioneering biotechnology company developing next-generation CAR T-cell therapies. The versatile CARKeyTM platform is designed to address barriers to success in treating solid tumours, thus reaching patients with critical unmet clinical need. Backed by a leadership team with proven success in cell therapy development, ImmunoKey is poised to unlock new possibilities in cancer immunotherapy.
Tiina Kähkönen
Chief Scientific Officer at OncoBone Therapeutics Ltd
Robert Learny
Founder & CEO of Accunea
Katie Lips
Founder of Eaitful
Fiona Marston
CEO of ErebagenErebagen is a synthetic biology company with a proprietary platform to discover optimise & scale-up novel bioactive products & biocatalysts by activating silent microbial gene clusters for Pharma Agbio, Industrial Biotech & other uses
John McKinley
CEO & Director of Imspex Diagnostics Ltd
Simon Mifsud
CEO of Garland Surgical
Ajay Mistry
Founder/CEO of Oppilotech
Georgia Mitsi
CEO of Sentinal4D
Irina Nazarenko
Scientific Advisor at CapCo Bio
Ajith Kumar Perakathu Somasekharan
Founder & CEO of Intelligent Assist
Helen Philippou
CEO of ClotProtect TherapeuticsHelen Philippou is a Professor of Translational Medicine at the University of Leeds. Recently she co-founded and is CEO of ClotProtect Therapeutics a spin-out company developing a small molecule therapeutic to stem bleeding in patients. Previously she co-founded LUNAC Therapeutics which was shortlisted for 4 "Start-up" awards and won 3 of these in 2020 and 2021. LUNAC was featured in J.P. Morgan's first-ever Top 200 Female-Powered Businesses report, where LUNAC was rated 55 out of 6,085 UK high-growth companies in 2021. . Prof Philippou also featured as a Mover and Shaker in 2021 BioBusiness Report, BioBeat.
Chris Phillips
Cso at Digistain Ltd.I have worked in the Imperial Physics Dept most of my career, apart from spells in UCSB California and the BBC. My research started of as semiconductor spectroscopy, but lately I've applied the techniques to healthcare. I have published>350 papers, had 37 PhD students, 24 PDRA's a £30M grant income, and am a Fellow of the Institute of Physics and the Royal Society of chemistry. a
Roghaiyeh Safari
CSO at RS & RS SCIENTIFIC
Sushanth Shetty
CEO of OncoAssign
Nick Sireau
CEO and Co-founder of Serenatis Bio
Richard Stead
Director of Qures Group Ltd
Kelvin Stott
Founder & CEO of Amporin Pharmaceuticals AG
Janette Thomas
CEO of Five Alarm Bio LtdCEO of Five Alarm Bio since mid 2022. Janette has a background in Biochemistry research at Leicester and Cambridge Universities, after which she has had 25years of pharmaceutical drug discovery and development experience from large Pharma (GSK) and SME’s. She has been instrumental in the early strategy and growth of small companies including Horizon Discovery (now a public company). She was Director of International Operations at Atlantic Healthcare until she founded Pellis Care Ltd. As a member of leadership teams, Janette has broad experience in developing company and product R&D strategy.
Dermot Tierney
COO at AMPLY DiscoveryAMPLY Discovery uses machine learning and synthetic biology to mine vast biological datasets to discover novel drug and nutraceutical candidates. Using a proprietary in silico and in vitro platform AMPLY is discovering best-in-class molecules to tackle some of humankind's greatest challenges such as cancer, MDR infections and metabolic diseases.
Leah Vanono
Founder of PBS Innovations
Léa Wenger
CEO and Co-Founder of Cycle Therapeutics